References
- Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 2005;174:1282–6.
- Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006;176:985–90.
- Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244–8.
- Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–41.
- King CR. The timing of salvage radiotherapy after radical prostatectomy: A systematic review. Int J Radiat Oncol Biol Phys 2011;84:104–11.
- Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancer 2013;5:1676–90.
- Lowes L, Lock M, Rodrigues G, D Souza D, Bauman G, Ahmad B, et al. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clin Trans Oncol 2012;14:150–6.
- Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Canc Res 2004;10:6897–904.